Several US states are actively advancing ibogaine-related legislation, most commonly through bills that authorize supervised clinical research, create study committees, or establish veteran-focused treatment pilot programs. No state has fully legalized ibogaine — it remains Schedule I federally under the Controlled Substances Act — but the legislative momentum in states like Texas, Utah, Indiana, and Vermont signals a rapidly shifting landscape for researchers and patients watching this space.

Legal Status Notice: Ibogaine is a Schedule I controlled substance under federal law (21 U.S.C. § 812), meaning it is illegal to manufacture, distribute, or possess in the United States without a DEA research registration. State-level bills do not override federal law. Nothing in this article constitutes legal advice or encourages illegal activity.

Why Are States Taking the Lead on Ibogaine?

Federal action on ibogaine has been slow despite growing clinical evidence. A landmark 2023 study published in Nature Medicine by Stanford researchers — examining Special Operations Forces veterans — found significant reductions in PTSD symptoms, depression, and anxiety following ibogaine-assisted therapy conducted in Mexico. That high-profile data, combined with a well-documented opioid crisis and a vocal veteran advocacy community, has pushed state legislators to act where Washington has not.

States have historically been laboratories for drug policy reform. The same pattern that preceded federal cannabis rescheduling discussions is now playing out with psychedelics. Ibogaine, because of its unique pharmacology as both an addiction interrupter and a dissociative psychedelic, occupies a distinct category that many legislators — particularly those focused on veteran health and opioid recovery — find compelling.

Which States Have Passed or Introduced Ibogaine Bills?

Texas — The Furthest Along

Texas is the most significant state actor on ibogaine to date. In 2023, the legislature passed SB 2308, directing the Texas Health and Human Services Commission to study ibogaine and MDMA as treatments for veterans with PTSD, traumatic brain injury, and substance use disorders. The bill authorized a supervised clinical trial framework and appropriated funding for research partnerships. Texas does not legalize ibogaine for general use — it specifically creates a pathway for veteran-focused, medically supervised research, which is a model other states are watching closely.

Utah — Research Authorization

Utah passed HB 167 in 2024, which directed the state's Department of Health and Human Services to study several psychedelic compounds including ibogaine for therapeutic use. The bill focused on establishing clinical research protocols and reporting requirements, stopping short of any decriminalization or access framework but creating the bureaucratic infrastructure for future action.

Indiana — Study Committee Approach

Indiana's SB 295 (2024) established a legislative study committee on psychedelic-assisted therapy, with ibogaine explicitly included in the scope of compounds under review. Study committees rarely generate immediate law, but they produce official state reports that inform future legislation and signal political willingness to engage the topic seriously.

Vermont — Therapy Access Study

Vermont introduced H.72 in 2025 to establish a Psychedelic Therapy Study Committee tasked with examining regulated access models for several substances, including ibogaine. Vermont's approach is notable for its emphasis on a regulated therapeutic access model rather than purely research framing, which pushes the policy conversation further than most states have gone.

Florida — Research Bill Introduction

Florida introduced SB 1582 in 2024, covering psychedelic therapy research broadly. While the bill did not advance through the full legislative process, its introduction in a large, politically conservative state reflects the bipartisan appeal ibogaine carries — particularly when framed around veteran welfare and opioid addiction, both issues with deep resonance in Florida.

Colorado — Broader Psychedelic Framework

Colorado's voter-approved Proposition 122 (2022), the Natural Medicine Health Act, created a regulated access framework for several natural psychedelics. Ibogaine was notably not included in the initial list of regulated substances, primarily due to its cardiac safety profile requiring more clinical infrastructure. However, the Colorado Natural Medicine Advisory Board has flagged ibogaine for future review as the regulatory system matures.

What Are the Most Common Legislative Approaches?

State bills on ibogaine tend to cluster around three models:

  • Research Authorization: Directs a state agency to fund or facilitate clinical trials under existing federal DEA research registration rules. Texas and Utah follow this model.
  • Study Committee: Creates a legislative or executive body to produce a report with policy recommendations. Indiana and Vermont have used this approach as a first step.
  • Regulated Access Framework: Establishes a licensing system for practitioners and supervised use centers, similar to Oregon's psilocybin model. No state has fully enacted this for ibogaine yet, but Vermont's H.72 gestures in this direction.

A veteran-specific framing is the most politically durable across party lines. Bills that center ibogaine as a treatment for combat veterans with PTSD or TBI consistently attract Republican co-sponsors in states where broader psychedelic legislation would face immediate opposition.

What Safety Considerations Are Shaping Legislative Language?

Cardiac Risk: Ibogaine carries a known risk of QT interval prolongation, which can lead to fatal cardiac arrhythmia. Deaths have been reported in unmonitored settings. Every state bill that has advanced includes provisions requiring medical screening, cardiac monitoring, and physician oversight. Researchers consistently emphasize that ibogaine should never be used outside a medically supervised environment.

Legislative drafters are paying close attention to the medical infrastructure requirements that distinguish ibogaine from other psychedelics. Bills increasingly specify requirements such as pre-treatment electrocardiograms, on-site cardiac monitoring, exclusion criteria for patients with cardiac risk factors, and the involvement of licensed physicians rather than facilitators alone. This is more stringent language than that found in psilocybin legislation, reflecting ibogaine's narrower therapeutic window.

How Does Federal Law Affect What States Can Actually Do?

Even when a state passes an ibogaine bill, federal Schedule I status under the Controlled Substances Act limits what can legally occur within state borders. Researchers at state institutions must obtain a DEA Schedule I researcher registration, which is a lengthy process. State funding can support study design, participant recruitment, and data collection infrastructure, but the drug itself cannot be legally manufactured or distributed without federal authorization.

The practical result is that most current state legislation creates frameworks and appropriates funds that can only be fully activated if federal policy changes — either through DEA rescheduling, expanded research exemptions, or congressional action like the proposed Breakthrough Therapies for Veterans Act, which has been introduced at the federal level with bipartisan support. State bills are therefore partly symbolic pressure tools designed to accelerate federal movement.

What Should Patients and Families Know Right Now?

State legislative activity does not create legal access to ibogaine for private individuals in those states. People currently seeking ibogaine treatment most often travel to licensed clinics in Mexico, Canada, or countries in Europe and the Caribbean where ibogaine is legal or unscheduled. This carries its own risks — quality of medical oversight varies enormously between facilities, and travel to another country for treatment means operating outside the US healthcare system's protections.

If you or someone you care about is researching ibogaine for opioid use disorder or PTSD, the safest near-term path is to consult with an addiction medicine specialist or psychiatrist familiar with psychedelic-assisted therapy, follow developments in state-authorized clinical trials (which may eventually open enrollment), and work with a legal professional if navigating treatment options abroad.

Frequently Asked Questions

No. Ibogaine remains Schedule I under federal law, which applies in all 50 states. State bills that have passed — including Texas SB 2308 — authorize research frameworks or study committees, not legal personal use or possession. Operating under a state research bill still requires federal DEA registration.
Texas SB 2308 (2023) directed the Texas Health and Human Services Commission to research ibogaine and MDMA as treatments for veterans with PTSD, TBI, and substance use disorders. It authorized and funded supervised clinical trials and required reporting back to the legislature. It did not decriminalize or legalize ibogaine for general use.
Ibogaine has a documented risk of fatal cardiac arrhythmia due to QT interval prolongation, which psilocybin does not share to the same degree. This means legislative frameworks for ibogaine consistently require more intensive medical infrastructure — cardiologist involvement, ECG screening, on-site monitoring — making a simple facilitated-access model like Oregon's psilocybin program less applicable.
A very limited number of FDA-authorized ibogaine research studies have been registered in the US. Eligibility requirements are strict and enrollment is limited. You can search ClinicalTrials.gov for active ibogaine studies. Most currently active clinical research is taking place in countries where ibogaine is not controlled, such as New Zealand, Brazil, and several European nations.
It appears to be the most bipartisan pathway currently. Texas SB 2308 passed in a Republican-dominated legislature precisely because it was framed around veteran care. The 2023 Stanford Nature Medicine study, which focused on Special Operations Forces veterans, has been widely cited by both conservative and progressive legislators as justification for expanded research. Veteran advocacy groups have been instrumental in lobbying for these bills.
Not currently. Colorado's Natural Medicine Health Act (Proposition 122, 2022) covers psilocybin, psilocin, DMT, mescaline, and ibogaine was excluded from the initial regulated substances list. The Colorado Natural Medicine Advisory Board has the authority to recommend adding substances in the future, and ibogaine has been identified for potential future review as clinical evidence and safety protocols develop.
Not automatically. Federal rescheduling or expanded research exemptions would remove the primary legal barrier, but states would still need to build out their own regulatory frameworks — licensing, safety standards, practitioner training, and oversight bodies. States that have already passed research authorization bills or established study committees would have a significant head start in that process.

The state legislative landscape around ibogaine is evolving quickly, and information that was accurate months ago may already be outdated. If you are a patient, family member, veteran, or researcher navigating this space, consult with a licensed addiction medicine physician or psychiatrist who is current on psychedelic research, and work with a legal professional before making any decisions involving substances that remain federally controlled. Advocacy organizations focused on veteran mental health and psychedelic policy reform can also connect you with the most current information on trial enrollment and legislative developments.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.